Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug

 
• By Brenda Sandburg
  
startup on track
Vistagen believes it is on track to begin a pivotal Phase III trial for its lead drug candidate • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D